Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • Topical calcineurin...

    Topical calcineurin inhibitors show favorable therapeutic response in Vitiligo

    Written by Medha Baranwal Baranwal Published On 2019-06-16T20:10:40+05:30  |  Updated On 19 Aug 2021 5:17 PM IST

    Treatment with topical calcineurin inhibitors (TCIs) both as a monotherapy and in combination with phototherapy, should be encouraged in patients with vitiligo -- is the bottom line of a recent study published in the journal JAMA Dermatology. Both the treatments (phototherapy and TCI) have synergistic effects.


    Vitiligo is a disease that causes the loss of skin colour in blotches. It affects about 0.5% to 1% of the population and is associated with low self-esteem and social stigma.


    "Topical calcineurin inhibitor monotherapy appears to produce a favourable therapeutic response, especially in children and in lesions on the face and neck. Therefore, TCI monotherapy is worth attempting when phototherapy is not available for the treatment of face and neck lesions, particularly in children," write the authors.


    Considering the high recurrence rate of vitiligo, the additional proactive use of TCIs to maintain remission of vitiligo could be promising.


    Topical calcineurin inhibitors including tacrolimus and pimecrolimus possess a dual mechanism of action for the treatment of vitiligo: immunosuppression and melanocyte induction.


    TCIs are recommended as first-line treatments for limited forms of vitiligo, however, the efficacy of TCI monotherapy is often underestimated. Ji Hae Lee, Department of Dermatology, St Vincent's Hospital, College of Medicine, Seoul, Korea, and colleagues conducted the study to estimate the treatment responses to both TCI monotherapy and TCI in combination with phototherapy for vitiligo, based on relevant prospective studies, and to systematically review the mechanism of action of TCIs for vitiligo treatment.


    For the purpose, the researchers conducted a comprehensive search of the database inception to August 6, 2018. The main keywords used were vitiligo, a topical calcineurin inhibitor, tacrolimus, pimecrolimus, and FK506.


    Of 250 studies initially identified, the full texts of 102 articles were assessed for eligibility. A total of 56 studies were identified: 11 studies on the TCI mechanism, 36 studies on TCI monotherapy, 12 studies on TCI plus phototherapy, and 1 study on TCI maintenance therapy.


    The primary outcomes were the rates of at least mild (≥25%), at least moderate (≥50%), and marked (≥75%) repigmentation responses to treatment. These rates were calculated by dividing the number of participants in an individual study who showed the corresponding repigmentation by the total number of participants who completed that study.


    Also Read: Alemtuzumab may lead to Vitiligo in multiple sclerosis patients

    Key findings of the study include:

    • In the 56 studies included in the analysis, 46 (1499 patients) were selected to evaluate treatment response.

    • For TCI monotherapy, an at least mild response was achieved in 55.0% of 560 patients in 21 studies, an at least moderate response in 38.5% of 619 patients in 23 studies, and a marked response in 18.1% of 520 patients in 19 studies after median treatment duration of 3 months (range, 2-7 months).

    • In the subgroup analyses, face and neck lesions showed an at least mild response in 73.1% of patients and a marked response in 35.4% of patients.

    • For TCI plus phototherapy, an at least mild response to TCI plus phototherapy was achieved in 89.5% of patients, and a marked response was achieved in 47.5% of patients.


    Also Read: EDF Guidelines for Vitiligo Management

    "The use of TCIs, both as a monotherapy and in combination with phototherapy, should be encouraged in patients with vitiligo, stresses the authors.


    To read the complete study follow the link: doi:10.1001/jamadermatol.2019.0696

    face lesionsJAMA DermatologyJi Hae Leemelanocytemonotherapyneck lesionsphototherapypimecrolimusskin disordertacrolimusTCI plus phototherapytopical calcineurin inhibitorstreatment responsevitiligovitiligo treatment

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok